JCI – Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

Clinical MedicineVirology Free access | 10.1172/JCI151697 Colin F. Pawlowski,2 John C. O’Horo,1 Lori L. Arndt,3 Richard F. Arndt,3 Sarah J. Bell,1 Dennis M. Bierle,1